Print this Page
Medical Oncology
Topics in This Section
- Paul Engstrom, MD
- Michael H. Levy, MD, PhD
- David Eli Adelberg MD
- Igor Astsaturov MD, PhD
- Marijo Bilusic, MD, PhD
- Hossein Borghaei, DO
- Barbara Ann Burtness, MD
- Jonathan D. Cheng, MD
- Marcin Chwistek, MD
- Adam D. Cohen, MD
- Steven J. Cohen, MD
- Crystal S Denlinger, MD
- Efrat Dotan, MD
- Scot W Ebbinghaus, MD
- Omotayo Fasan, MD
- Richard I. Fisher, MD
- Lori J. Goldstein, MD
- Gary R. Hudes, MD
- Angela Jain, MD
- Michael J. Kane MD, FACP
- Thomas R Klumpp, MD, FACP
- Patricia L. Kropf, MD
- Gregory Michael Lubiniecki, MD
- Kenneth F. Mangan, MD, FACP
- Lainie P. Martin, MD
- Mary Ellen Martin, MD
- Ranee Mehra, MD
- Michael M. Millenson, MD
- Tara Morrison, MD, FRCP(c)
- Sujana Movva, MD
- Anthony J. Olszanski, MD, RPh
- Elizabeth R. Plimack, MD, MS
- Manish Sharma, MD
- Joseph Treat, MD
- Margaret von Mehren, MD
- Yu-Ning Wong, MD
The Medical Oncology department provides quality diagnosis, treatment, and care for patients with cancer.
Medical Oncology Staff List
Paul F. Engstrom, MD,
Acting Director, Medical Oncology
Hossein Borghaei, DO,
Chief, Thoracic Medical Oncology
Barbara Burtness, MD,
Chief, Head and Neck Medical Oncology, Medical Oncology
Steven J. Cohen MD,
Chief, Gastrointestinal Medical Oncology
Scot W. Ebbinghaus, MD, Attending Physician, Medical Oncology
Omotayo Fasan, MBBS, MRCP (UK),
Attending Physician, Bone Marrow Transplant
Lori Goldstein, MD,
Director, The Naomi and Phil Lippincott Breast Evaluation Center
Gregory Michael Lubiniecki, MD
Kenneth F. Mangan, MD, FACP,
Director, Bone Marrow Transplant Program
Michael M. Millenson, MD,
Director, Hematology Service
Anthony J. Olszanski, MD, RPh,
Director, Clinical Pharmacology
Manish Sharma, MD,
Assistant Director, Bone Marrow Transplant Program, Medical Oncology
Margaret von Mehren, MD ,
Director, Sarcoma Program
Pain and Palliative Care
Michael H Levy, MD, PhD,
Vice Chair, Medical Oncology
Advanced Practice Clinicians
Colleen H Erb, MSN, CRNP, ACNP-BC,
Nurse Practitioner, Medical Oncology/Hematology
Kristen Kreamer, CRNP, MSN, AOCN, APRN-BC
Ann Pellegrino, OCN, MSN, ANP-BC
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Eric Tetzlaff, PA-C, Physician Assistant, Medical Oncology
Kathryn Tumelty, MSN, AOCNP
Traditional chemotherapy and new clinical trials provide our Medical Oncologists with access to a tremendous range of new anticancer treatments, including medicines and combinations of medicines.
"Personalized" treatment involves identifying characteristics of individual patients' tumors in order to determine their responsiveness to specific chemotherapy drugs. The ultimate goal of such analysis is to determine which tumors are sensitive to a given drug and equally important, which tumors are resistant to specific drugs.
A similar approach has already benefited the Fox Chase Gastrointestinal Cancer program, where patients with metastatic colorectal cancer are routinely screened for mutations in the K-RAS gene to determine the most effective drug treatment. Fox Chase's Clinical Molecular Genetics Laboratory has been conducting this test since 2007.
This focus on personalized medicine is just another example of Fox Chase's leadership in bringing state-of-the-art research directly to the bedside and delivering expert and compassionate care with the goal of improving patient outcomes.
